Patents by Inventor Alagu P. Thiruvengadam
Alagu P. Thiruvengadam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210196697Abstract: The present invention relates to pharmaceutical combinations and compositions, and methods of using the same for treatment of attention deficit hyperactivity disorder (ADHD) and bipolar disorder (BD). The invention relates to combination therapies for the treatment of BD and for ADHD, and methods for treating BD and ADHD using such therapies. The present invention also relates to methods of determining an optimal combination drug treatment therapy for BD and for ADHD, methods of optimizing a combination drug treatment therapy for BD and for ADHD, methods of optimizing dosage of a drug in a combination drug treatment therapy for BD and for ADHD, as well as methods for monitoring the efficacy of a combination therapy for the treatment of BD and for ADHD. The present invention involves analyzing the membrane potential of cells isolated from a BD patient treated with the combination therapy and from an ADHD patient treated with the combination therapy, and calculating a membrane potential ratio therefrom.Type: ApplicationFiled: October 24, 2018Publication date: July 1, 2021Applicant: PsychNostics, LLCInventor: Alagu P. THIRUVENGADAM
-
Publication number: 20190309285Abstract: The present invention relates to a composition comprising a plurality of cDNA molecules for use in methods of detecting changes in expression of genes encoding proteins that are associated with mental illnesses and which are differentially expressed in patients with mental illnesses, such as bipolar I disorder, bipolar II disorder, unipolar disorder, schizophrenia. attention deficit hyperactive disorders, obsessive compulsive disorders, anxiety disorders or other related mood disorders. The composition and the cDNA molecules may be used in their entirety or in part as to diagnose. to stage, to treat. and/or to monitor the treatment of a subject with mental illness.Type: ApplicationFiled: April 8, 2019Publication date: October 10, 2019Applicant: PsychNostics, LLCInventors: Alagu P. THIRUVENGADAM, Krish CHANDRASEKARAN
-
Publication number: 20190302102Abstract: The present invention relates to pharmaceutical combinations and compositions, and methods of using the same for treatment of Bipolar Disorder (BD). More specifically, the invention relates to combination therapies for the treatment of BD, and methods for treating BD using such therapies. The present invention also relates to methods of determining an optimal combination drug treatment therapy for BD, methods of optimizing a combination drug treatment therapy for BD, methods of optimizing dosage of a drug in a combination drug treatment therapy for BD, as well as methods for monitoring the efficacy of a combination therapy for the treatment of BD. The present invention involves analyzing the membrane potential of cells isolated from a BD patient treated with the combination therapy, and calculating a membrane potential ratio therefrom.Type: ApplicationFiled: October 26, 2017Publication date: October 3, 2019Applicant: PsychNostics, LLCInventor: Alagu P. THIRUVENGADAM
-
Publication number: 20190293633Abstract: The present invention provides methods to modulate key elements along the DAG signaling pathway as well as a diagnostic assay, device and methods of using the same to diagnose bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods to identify diagnostic markers and drug targets for BD and ADHD. Methods of identifying effective compounds responsible for membrane potentials and excitabilities influencing bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods of identifying an effective compound that modulates the activity of Ca2+/CaM enzyme and compounds involved in changing the K+ gradient across the plasma membrane thereby increasing or decreasing the membrane potential ratio (MPR™) values. The invention provides methods of identifying a compound that modulates the activity of PKC which is an important protein of the DAG signaling pathway.Type: ApplicationFiled: June 12, 2019Publication date: September 26, 2019Applicant: PsychNostics, LLCInventor: Alagu P. THIRUVENGADAM
-
Patent number: 10365268Abstract: The present invention provides methods to modulate key elements along the DAG signaling pathway as well as a diagnostic assay, device and methods of using the same to diagnose bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods to identify diagnostic markers and drug targets for BD and ADHD. Methods of identifying effective compounds responsible for membrane potentials and excitabilities influencing bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods of identifying an effective compound that modulates the activity of Ca2+/CaM enzyme and compounds involved in changing the K+ gradient across the plasma membrane thereby increasing or decreasing the membrane potential ratio (MPR™) values. The invention provides methods of identifying a compound that modulates the activity of PKC which is an important protein of the DAG signaling pathway.Type: GrantFiled: September 26, 2016Date of Patent: July 30, 2019Assignee: PsychNostics, LLCInventor: Alagu P. Thiruvengadam
-
Patent number: 10301615Abstract: The present invention relates to a composition comprising a plurality of cDNA molecules for use in methods of detecting changes in expression of genes encoding proteins that are associated with mental illnesses and which are differentially expressed in patients with mental illnesses, such as bipolar I disorder, bipolar II disorder, unipolar disorder, schizophrenia, attention deficit hyperactive disorders, obsessive compulsive disorders, anxiety disorders or other related mood disorders. The composition and the cDNA molecules may be used in their entirety or in part as to diagnose, to stage, to treat, and/or to monitor the treatment of a subject with mental illness.Type: GrantFiled: January 30, 2014Date of Patent: May 28, 2019Assignee: PsychNostics, LLCInventors: Alagu P. Thiruvengadam, Krish Chandrasekaran
-
Patent number: 10082498Abstract: The present invention relates to a method for optimizing drug therapy treatment of patients with Attention Deficit Hyperactivity Disorder (ADHD) or Bipolar Disorder (BD), a method of optimizing drug dosage for treatment of ADHD and BD, a method of treating ADHD and BD, and a kit. The present method may also be used to adjust medication doses for individual patients.Type: GrantFiled: May 15, 2014Date of Patent: September 25, 2018Assignee: PsychNostics, LLCInventors: Alagu P. Thiruvengadam, Douglas B. Woodruff
-
Publication number: 20170010255Abstract: The present invention provides methods to modulate key elements along the DAG signaling pathway as well as a diagnostic assay, device and methods of using the same to diagnose bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods to identify diagnostic markers and drug targets for BD and ADHD. Methods of identifying effective compounds responsible for membrane potentials and excitabilities influencing bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods of identifying an effective compound that modulates the activity of Ca2+/CaM enzyme and compounds involved in changing the K+ gradient across the plasma membrane thereby increasing or decreasing the membrane potential ratio (MPR™) values. The invention provides methods of identifying a compound that modulates the activity of PKC which is an important protein of the DAG signaling pathway.Type: ApplicationFiled: September 26, 2016Publication date: January 12, 2017Applicant: PsychNostics, LLCInventor: Alagu P. THIRUVENGADAM
-
Patent number: 9523673Abstract: The present invention provides methods to modulate key elements along the DAG signaling pathway as well as a diagnostic assay, device and methods of using the same to diagnose bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods to identify diagnostic markers and drug targets for BD and ADHD. Methods of identifying effective compounds responsible for membrane potentials and excitabilities influencing bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods of identifying an effective compound that modulates the activity of Ca2+/CaM enzyme and compounds involved in changing the K+ gradient across the plasma membrane thereby increasing or decreasing the membrane potential ratio (MPR™) values. The invention provides methods of identifying a compound that modulates the activity of PKC which is an important protein of the DAG signaling pathway.Type: GrantFiled: September 14, 2012Date of Patent: December 20, 2016Assignee: PsychNostics, LLCInventor: Alagu P. Thiruvengadam
-
Publication number: 20160084826Abstract: The present invention relates to a method for optimizing drug therapy treatment of patients with Attention Deficit Hyperactivity Disorder (ADHD) or Bipolar Disorder (BD), a method of optimizing drug dosage for treatment of ADHD and BD, a method of treating ADHD and BD, and a kit. The present method may also be used to adjust medication doses for individual patients.Type: ApplicationFiled: May 15, 2014Publication date: March 24, 2016Applicant: PSYCHNOSTICS, LLC.Inventors: Alagu P. THIRUVENGADAM, Douglas B. WOODRUFF
-
Publication number: 20160002623Abstract: The present invention relates to a composition comprising a plurality of cDNA molecules for use in methods of detecting changes in expression of genes encoding proteins that are associated with mental illnesses and which are differentially expressed in patients with mental illnesses, such as bipolar I disorder, bipolar II disorder, unipolar disorder, schizophrenia, attention deficit hyperactive disorders, obsessive compulsive disorders, anxiety disorders or other related mood disorders. The composition and the cDNA molecules may be used in their entirety or in part as to diagnose, to stage, to treat, and/or to monitor the treatment of a subject with mental illness.Type: ApplicationFiled: January 30, 2014Publication date: January 7, 2016Applicant: PSYCHNOSTICS, LLCInventors: Alagu P. THIRUVENGADAM, Krish CHANDRASEKARAN
-
Publication number: 20140248652Abstract: The present invention provides methods to modulate key elements along the DAG signaling pathway as well as a diagnostic assay, device and methods of using the same to diagnose bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods to identify diagnostic markers and drug targets for BD and ADHD. Methods of identifying effective compounds responsible for membrane potentials and excitabilities influencing bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods of identifying an effective compound that modulates the activity of Ca2+/CaM enzyme and compounds involved in changing the K+ gradient across the plasma membrane thereby increasing or decreasing the membrane potential ratio (MPR™) values. The invention provides methods of identifying a compound that modulates the activity of PKC which is an important protein of the DAG signaling pathway.Type: ApplicationFiled: September 14, 2012Publication date: September 4, 2014Applicant: PSYCHNOSTICS, LLCInventor: Alagu P. Thiruvengadam
-
Patent number: 7906300Abstract: Changes that occur in Na+K+ ATPase regulation and therefore in the membrane potential in cells from bipolar individuals, as compared to cells from unaffected control individuals, are utilized to provide a diagnostic assay for bipolar I and bipolar II disorders. The diagnostic assay may also or instead exploit the similarity of cells from new patients to those of people already known to have bipolar I or bipolar II disorder. A similar diagnostic assay is provided for diagnosing attention-deficit/hyperactivity disorder (ADHD) and unipolar disorder. The diagnostic assays may further involve manipulation of membrane potential by incubation of cells in K+-free buffer and/or incubation with one or more compounds that alter Na+K+ ATPase activity. Although a variety of cells may be used, the diagnostic assays preferably employ lymphoblasts or whole blood cells.Type: GrantFiled: April 3, 2006Date of Patent: March 15, 2011Assignee: PsychNostics, LLCInventors: Alagu P. Thiruvengadam, Krish Chandrasekaran
-
Patent number: 7425410Abstract: Changes that occur in Na+K+ ATPase regulation and therefore in the membrane potential in cells from bipolar individuals, as compared to cells from unaffected control individuals, are utilized to provide a diagnostic assay for a bipolar disorder. The diagnostic assay may also or instead exploit the similarity of cells from bipolar patients to those of people already known to have a bipolar disorder. A similar diagnostic assay is provided for diagnosing unipolar disorder. The diagnostic assays may further involve manipulation of membrane potential by incubation of cells in K+-free buffer and/or incubation with one or more compounds that alter Na+K+ ATPase activity. Although a variety of cells may be used, the diagnostic assays preferably employ lymphoblasts or whole blood cells.Type: GrantFiled: April 14, 2004Date of Patent: September 16, 2008Assignee: Free State Diagnostics, LLCInventors: Alagu P. Thiruvengadam, Krish Chandrasekaran
-
Publication number: 20080160554Abstract: Changes that occur in Na+K+ ATPase regulation and therefore in the membrane potential in cells from bipolar individuals, as compared to cells from unaffected control individuals, are utilized to provide a diagnostic assay for bipolar I and bipolar II disorders. The diagnostic assay may also or instead exploit the similarity of cells from new patients to those of people already known to have bipolar I or bipolar II disorder. A similar diagnostic assay is provided for diagnosing attention-deficit/hyperactivity disorder (ADHD) and unipolar disorder. The diagnostic assays may further involve manipulation of membrane potential by incubation of cells in K+-free buffer and/or incubation with one or more compounds that alter Na+K+ ATPase activity. Although a variety of cells may be used, the diagnostic assays preferably employ lymphoblasts or whole blood cells.Type: ApplicationFiled: April 3, 2006Publication date: July 3, 2008Applicant: Free State Diagnostics, LLCInventors: Alagu P. Thiruvengadam, Krish Chandrasekaran
-
Patent number: 4231259Abstract: A non-destructive evaluation technique particularly suited for in situ testing utilizes significant changes in internal friction damping (IFD) as an indicating factor. A baseline for the specific damping capacity of an object is determined and a tolerance range is established from the baseline. Measurements of the specific damping capacity are periodically made and checked to see if they are within the tolerance range. Unexpected changes in specific damping capacity indicate the presence of an incipient flaw in the object. The evaluation technique can also be used to locate flaws, monitor crack growth and predict useful life. Apparatus for measuring specific damping capacity is also disclosed.Type: GrantFiled: August 11, 1978Date of Patent: November 4, 1980Inventors: Alagu P. Thiruvengadam, Ambrose A. Hochrein, Jr.
-
Patent number: 4193635Abstract: A process and apparatus for high speed material removal with relatively low specific energy input requirements are disclosed. The apparatus includes a system for supplying pressurized fluid at a predetermined flow rate and pressure to an orifice of predetermined diameter. The system establishes a fluid flow to an environment in which there exists cavitation downstream of the orifice. The orifice size, position relative to the surface being treated, the fluid velocity and fluid pressure are determined with reference to the erosion strength of the particular parent material to be removed so as to effect highly efficient rapid cutting, drilling, cleaning and the like. The process includes the generation of a cavitation-free fluid flow through the orifice such that a submerged cavitating flow field is established downstream of that orifice. The velocity of fluid flowing through the orifice is selected to provide a cavitation intensity which exceeds the threshold erosion intensity of the material to be removed.Type: GrantFiled: April 7, 1978Date of Patent: March 18, 1980Inventors: Alagu P. Thiruvengadam, Ambrose A. Hochrein, Jr.
-
Patent number: 4127332Abstract: A method and apparatus are disclosed for the homogenization of a multicomponent stream including a liquid and a substantially insoluble component, which may be either a liquid or a finely divided solid. The homogenization process is effected by passing the multicomponent, fluid stream through a turbulent shear layer having a substantial velocity gradient there-across and designed such that turbulent vortical eddies generate a cavitating flow regime. The cavitating flow regime allows the generation of vapor bubbles which move downstream into a region of pressure and violently collapse. The violent bubble collapse creates intense pressure pulses which cause the intimate intermixing of the liquid and the substantially insoluble component such that the effluent, a resulting emulsion, has an exceptionally long separation half-life with a very high emulsification coefficient.Type: GrantFiled: November 19, 1976Date of Patent: November 28, 1978Assignee: Daedalean Associates, Inc.Inventors: Alagu P. Thiruvengadam, Ambrose A. Hochrein, Jr.